Acadia Pharmaceuticals Inc. is rated Buy for its steady NUPLAZID/DAYBUE franchises and pipeline-driven upside potential. NUPLAZID’s patent protection now extends to 2030, supporting >10% Y/Y revenue ...
Swing trading sits between day trading and long-term investing. Many, or all, of the products featured on this page are from our advertising partners who compensate us when you take certain actions on ...
Wealthfront just became the first publicly traded robo-advisor. Shares of the wealth management company opened at $14 and moved higher in Friday afternoon trading, ending the day at $14.19 per share, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback